PL367308A1 - Novel use - Google Patents
Novel useInfo
- Publication number
- PL367308A1 PL367308A1 PL02367308A PL36730802A PL367308A1 PL 367308 A1 PL367308 A1 PL 367308A1 PL 02367308 A PL02367308 A PL 02367308A PL 36730802 A PL36730802 A PL 36730802A PL 367308 A1 PL367308 A1 PL 367308A1
- Authority
- PL
- Poland
- Prior art keywords
- novel use
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0112208A GB0112208D0 (en) | 2001-05-18 | 2001-05-18 | New use |
| GB0129268A GB0129268D0 (en) | 2001-12-06 | 2001-12-06 | Novel use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL367308A1 true PL367308A1 (en) | 2005-02-21 |
Family
ID=26246093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02367308A PL367308A1 (en) | 2001-05-18 | 2002-05-17 | Novel use |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1387687A4 (en) |
| JP (1) | JP2004534761A (en) |
| KR (1) | KR20040016865A (en) |
| CN (1) | CN1269483C (en) |
| AR (1) | AR045879A1 (en) |
| AU (1) | AU2002303811B2 (en) |
| BR (1) | BR0209662A (en) |
| CA (1) | CA2447063A1 (en) |
| CZ (1) | CZ20033115A3 (en) |
| HU (1) | HUP0400966A2 (en) |
| IL (1) | IL158701A0 (en) |
| MX (1) | MXPA03010509A (en) |
| MY (1) | MY134211A (en) |
| NO (1) | NO20035121L (en) |
| NZ (1) | NZ529462A (en) |
| PE (1) | PE20021067A1 (en) |
| PL (1) | PL367308A1 (en) |
| TW (1) | TWI243678B (en) |
| WO (1) | WO2002094187A2 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1911763B1 (en) | 2003-01-28 | 2010-08-11 | Ironwood Pharmaceuticals, Inc. | Compositions for the treatment of gastrointestinal disorders |
| AU2005231355B2 (en) * | 2004-03-30 | 2008-09-18 | Smithkline Beecham Corporation | Spray dried pharmaceutical compositions |
| WO2005100997A2 (en) * | 2004-04-16 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3) |
| JP2009510121A (en) * | 2005-09-30 | 2009-03-12 | スミスクライン・ビーチャム・コーポレイション | Pharmaceutical composition |
| TW200804288A (en) | 2005-12-12 | 2008-01-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (en) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS. |
| ES2522968T3 (en) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| MX381407B (en) | 2008-12-31 | 2025-03-12 | Ardelyx Inc | COMPOUNDS AND METHODS FOR INHIBITING SODIUM ION/HYDROGEN ION EXCHANGER (NHE)-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND DISORDERS OF THE GASTROINTESTINAL TRACT. |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| KR200452372Y1 (en) * | 2010-05-14 | 2011-02-22 | 서일수 | Communication line support device of construction lift |
| KR101034774B1 (en) * | 2010-07-30 | 2011-05-17 | (주)챔피온코리아 | Lift device using wire rope |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MX366293B (en) | 2012-08-21 | 2019-07-04 | Ardelyx Inc | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders. |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| HRP20191000T1 (en) | 2013-04-12 | 2019-09-20 | Ardelyx, Inc. | Nhe3-binding compounds and methods for inhibiting phosphate transport |
| WO2014170648A1 (en) | 2013-04-19 | 2014-10-23 | Astrazeneca Ab | A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) |
| BR112015030326A2 (en) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | ULTRAPURE GUANYLATE CYCLASE C AGONISTS, METHOD OF MANUFACTURING AND USING THEM |
| MX2019008171A (en) | 2017-01-09 | 2020-02-05 | Ardelyx Inc | Inhibitors of nhe-mediated antiport. |
| MX395405B (en) | 2017-01-09 | 2025-03-25 | Ardelyx Inc | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719311B1 (en) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Compounds that are selective antagonists of the human NK3 receptor and their use as drugs and diagnostic tools. |
| US5434158A (en) * | 1994-04-26 | 1995-07-18 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin-3 antagonists |
| AR004735A1 (en) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT. |
| EP0983262B1 (en) * | 1997-05-23 | 2003-07-09 | GlaxoSmithKline S.p.A. | Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists |
| JP2002530377A (en) * | 1998-11-20 | 2002-09-17 | スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
-
2002
- 2002-05-16 MY MYPI20021787A patent/MY134211A/en unknown
- 2002-05-17 KR KR10-2003-7014960A patent/KR20040016865A/en not_active Withdrawn
- 2002-05-17 MX MXPA03010509A patent/MXPA03010509A/en not_active Application Discontinuation
- 2002-05-17 CZ CZ20033115A patent/CZ20033115A3/en unknown
- 2002-05-17 PL PL02367308A patent/PL367308A1/en not_active Application Discontinuation
- 2002-05-17 WO PCT/US2002/015911 patent/WO2002094187A2/en not_active Ceased
- 2002-05-17 HU HU0400966A patent/HUP0400966A2/en unknown
- 2002-05-17 NZ NZ529462A patent/NZ529462A/en unknown
- 2002-05-17 PE PE2002000415A patent/PE20021067A1/en not_active Application Discontinuation
- 2002-05-17 CN CNB028101588A patent/CN1269483C/en not_active Expired - Fee Related
- 2002-05-17 AU AU2002303811A patent/AU2002303811B2/en not_active Ceased
- 2002-05-17 JP JP2002590908A patent/JP2004534761A/en active Pending
- 2002-05-17 EP EP02731870A patent/EP1387687A4/en not_active Withdrawn
- 2002-05-17 CA CA002447063A patent/CA2447063A1/en not_active Abandoned
- 2002-05-17 BR BR0209662-5A patent/BR0209662A/en not_active IP Right Cessation
- 2002-05-17 TW TW091110318A patent/TWI243678B/en active
- 2002-05-17 IL IL15870102A patent/IL158701A0/en unknown
- 2002-05-17 AR ARP020101845A patent/AR045879A1/en not_active Application Discontinuation
-
2003
- 2003-11-17 NO NO20035121A patent/NO20035121L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040016865A (en) | 2004-02-25 |
| CZ20033115A3 (en) | 2004-09-15 |
| WO2002094187A3 (en) | 2003-05-30 |
| EP1387687A2 (en) | 2004-02-11 |
| IL158701A0 (en) | 2004-05-12 |
| WO2002094187A2 (en) | 2002-11-28 |
| JP2004534761A (en) | 2004-11-18 |
| AU2002303811B2 (en) | 2005-07-07 |
| CN1509175A (en) | 2004-06-30 |
| PE20021067A1 (en) | 2003-02-02 |
| MXPA03010509A (en) | 2004-03-02 |
| NZ529462A (en) | 2005-07-29 |
| MY134211A (en) | 2007-11-30 |
| HUP0400966A2 (en) | 2004-08-30 |
| EP1387687A4 (en) | 2006-07-05 |
| TWI243678B (en) | 2005-11-21 |
| BR0209662A (en) | 2004-04-20 |
| NO20035121D0 (en) | 2003-11-17 |
| NO20035121L (en) | 2003-11-17 |
| CA2447063A1 (en) | 2002-11-28 |
| CN1269483C (en) | 2006-08-16 |
| AR045879A1 (en) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE50201180D1 (en) | Organopolysiloxan/polyharnstoff/polyurethan-blockcopolymere | |
| HU0401339D0 (en) | Novel 4-anilinoquinoline-3-carboxamides | |
| PL367308A1 (en) | Novel use | |
| GB0125088D0 (en) | New use | |
| GB0100762D0 (en) | Novel use | |
| GB0115181D0 (en) | Novel use | |
| GB0104554D0 (en) | New uses | |
| EG23036A (en) | Novel pyrrolecarboxamides | |
| GB0106031D0 (en) | Use | |
| PL364076A1 (en) | Novel pyridylmethylaminopyrimidines | |
| PL367864A1 (en) | Novel combination | |
| GB0119382D0 (en) | Voltsnips | |
| GB0119920D0 (en) | New use | |
| GB0118919D0 (en) | Novel use | |
| GB0129268D0 (en) | Novel use | |
| GB0119022D0 (en) | Novel use | |
| GB0100852D0 (en) | Novel use | |
| GB0129266D0 (en) | Novel use | |
| GB0103892D0 (en) | Use | |
| GB0126186D0 (en) | Use | |
| GB0108115D0 (en) | Use | |
| GB0102482D0 (en) | Use | |
| GB0103899D0 (en) | Use | |
| GB0130704D0 (en) | New use | |
| GB0112207D0 (en) | New use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |